Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters

PURPOSE: Drug-drug interaction (DDI) potentials of lusutrombopag, a thrombopoietin receptor agonist, on the activity of cytochrome P450 (CYP) 3A and of cyclosporine, which inhibits P-glycoprotein and breast cancer resistance protein, on lusutrombopag pharmacokinetics were assessed via clinical studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsube, Takayuki, Inoue, Yuji, Fukuhara, Takahiro, Kano, Takeshi, Wajima, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Pharmacokinetics and Disposition
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661413/
https://www.ncbi.nlm.nih.gov/pubmed/32666123
http://dx.doi.org/10.1007/s00228-020-02960-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661413/
https://www.ncbi.nlm.nih.gov/pubmed/32666123
http://dx.doi.org/10.1007/s00228-020-02960-7

Ejemplares similares